A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia

Urology

Volumn 47, Issue 3, 1996, Pages 335-342

  Elhilali, Mostafa M ^a,h   Ramsey, Ernest W ^b   Barkin, Jack ^c   Casey, Richard W ^d   Boake, Rex C ^e   Beland, Gilles ^f   Fradet, Yves ⁱ   Trachtenberg, John ^c   Orovan, William L ^g   Schick, Erik ^f   Klotz, Laurence H ^c  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d The Male Health Centre   (Canada)

^e UNIVERSITY OF ALBERTA   (Canada)

^f UNIVERSITÉ DE MONTRÉAL   (Canada)

^g MCMASTER UNIVERSITY   (Canada)

^h ROYAL VICTORIA HOSPITAL   (Canada)

ⁱ NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TERAZOSIN;

ADULT; AGED; AMBLYOPIA; ARTHRALGIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; RESIDUAL URINE; RHINITIS; URINE FLOW RATE; VERTIGO;

EID: 9044220970     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)80449-X     Document Type: Article

References (31)

1. Berry SJ, Coffey DS, Walsh PC, and Ewing LL: The development of human benign prostatic hyperplasia with age. J Urol 132: 474-479, 1984.
2. Kane MM, Fields DW, and Vaughan ED Jr: Medical management of benign prostatic hyperplasia. Urology 36: 5-12, 1990.
3. Holtgrewe HL, Mebust WK, Dowd JB, Cockett AT, Peters PC, and Proctor C: Transurethral prostatectomy: practice aspects of the dominant operation in American urology. J Urol 141: 248-253, 1989.
4. Mebust WK, Holtgrewe HL, Cockett AT, and Peters PC: Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 141: 243-247, 1989.
5. Lepor H, and Rigaud G: The efficacy of transurethral resection of the prostate in men with moderate symptoms of prostatism. J Urol 143: 533-537, 1990.
6. Wennberg JE, Roos N, Sola L, Schori A, and Jaffe R: Use of claims data systems to evaluate health care outcomes. Mortality and reoperation following prostatectomy. JAMA 257: 933-936, 1987.
7. Caine M, Raz S, and Zeigler M: Adrenergic and cholinergic receptors in the human prostate, prostate capsule and bladder neck. Br J Urol 47: 193-202, 1975.
8. Wilde MI, Fitton A, and Sorkin EM: Terazosin. A review of its pharmacodynamic and pharmacokineric properties, and therapeutic potential in benign prostatic hyperplasia. Drugs Aging 3: 258-277, 1993.
9. Morita T: (Quantitative analyses of human prostatic alpha-adrenoceptors and effects of terazosin on the alpha-adrenoceptor activity.) (Japanese) J Smooth Muscle Res 27: 149-154, 1991.
10. Caine M, Pfau A, and Perlberg S: The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol 48: 255-263, 1976.
11. Caine M, Perlberg S, and Meretyk S: A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol 50: 551-554, 1978.
12. Hedlund H, Andersson KE, and Ek A: Effects of prazosin in patients with benign prostatic obstruction. J Urol 130: 275-278, 1983.
13. Kirby RS, Coppinger SW, Corcoran MO, Chapple CR, Flannigan M, and Milroy EJ: Prazosin in the treatment of prostatic obstruction. A placebo-controlled study. Br J Urol 60: 136-142, 1987.
14. Matzkin H, Soloway MS, Rangel MC, and Laddu A: Efficacy of terazosin in patients with benign prostatic hyperplasia. Eur Urol 21: 126-130, 1992.
15. Park YC, Nishioka T, Arai Y, Tomoyoshi T, Kurita T, Hayashida H, Nagai N, Inoue H, Kataoka K, Kitagawa Y, et al: (A multicenter, fixed-flexible dose study of terazosin hydrochloride in the treatment of symptomatic benign prostatic hypertrophy.) (Japanese) Hinyokika Kiyo 38: 857-868, 1992.
16. Lepor H, Meretyk S, and Knapp-Maloney G: The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia. J Urol 147: 1554-1557, 1992.
17. Woods AL 3d: The management of symptomatic benign prostatic hyperplasia with the once-daily alpha 1 blocker, terazosin. Mil Med 157: 361-364, 1992.
18. Gleason DM, and Bottaccini MR: Effect of terazosin on urine storage and voiding in the aging male with prostatism. Neurourol Urodyn 13: 1-12, 1994.
19. Fabricius PG, Weizert P, Dunzendorfer U, Hannaford JM, and Maurath C: Efficacy of once-a-day terazosin in benign prostatic hyperplasia: a randomized, double-blind placebo-controlled clinical trial. Prostate (suppl 3): 85-93, 1990.
20. Lepor H, Henry D, and Laddu AR: The efficacy and safety of terazosin for the treatment of symptomatic BPH. Prostate 18: 345-355, 1991.
21. Lepor H, and Laddu A: Terazosin in the treatment of benign prostatic hyperplasia: the United States experience. (Review.) Br J Urol 70 (suppl 1): 2-9, 1992.
22. Fabricius PG, and Hannaford JM: Placebo-controlled study of terazosin in the treatment of benign prostatic hyperplasia with 2-year follow-up. Br J Urol 70 (suppl 1): 10-16, 1992.
23. Lloyd SN, Buckley JF, Chilton CP, Ibrahim I, Kaisary AV, and Kirk D: Terazosin in the treatment of benign prostatic hyperplasia: a multicentre, placebo-controlled trial. Br J Urol 70 (suppl 1): 17-21, 1992.
24. Di Silverio F: Use of terazosin in the medical treatment of benign prostatic hyperplasia: experience in Italy. Br J Urol 70 (suppl 1): 22-26, 1992.
25. Lepor H, Auerbach S, Puras-Baez A, Narayan P, Soloway M, Lowe F, Moon Y, Leifer G, and Madsen P: A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 148: 1467-1474, 1992.
26. Brawer MK, Adams G, and Epstein H: Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group. Arch Fam Med 2: 929-935, 1993.
27. 1 blocker, terazosin. Today's Ther Trends 11: 121, 1993.
28. Boyarsky S, Jones G, Paulson DF, and Prout GR Jr.: A new look at bladder neck obstruction by the Food and Drug Administration regulators: guidelines for investigation of benign prostatic hypertrophy. Trans Am Assoc Genitourin Surg 68: 29-32, 1976.
29. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, and Cockett AT: The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148: 1549-1557, 1992.
30. Lepor H, and Machi G: The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH. Prostate 20: 89-95, 1992.
31. Guthrie R: Terazosin in the treatment of hypertension and symptomatic benign prostatic hyperplasia: a primary care trial. J Fam Pract 39: 129-133, 1994.